Table 1.
Baseline characteristics of included patients.
| N = 576 | |
|---|---|
| Mean age at study entry, years (SD) | 45.2 (13) |
| Mean disease duration, years (SD) | 10.7 (6.4) |
| RRMS, n (%) | 432 (75) |
| SPMS, n (%) | 67 (11.6) |
| PPMS | 77 (13.4) |
| Female gender, n (%) | 403 (70) |
| Median EDSS, (SD) | 2.7 (2.0) |
| Interferon beta, n (%) | 84 (14.58) |
| Glatiramer acetate, n (%) | 43 (7.47) |
| Teriflunomide, n (%) | 50 (8.68) |
| Fingolimod, n (%) | 102 (17.71) |
| Dimethylfumarate, n (%) | 25 (4.34) |
| Natalizumab, n (%) | 48 (8.33) |
| Alemtuzumab, n (%) | 25 (4.34) |
| Ocrelizumab, n (%) | 33 (5.73) |
| Rituximab, n (%) | 9 (1.56) |
| Cladribine, n (%) | 37 (6.42) |
| No treatment | 120 (20.83) |
| Median Charlson score of comorbidities, (SD) | 0.23 (0.52) |
RRMS= relapsing remitting multiple sclerosis; SPMS= secondary progressive multiple sclerosis; PPMS= primary progressive multiple sclerosis; EDSS= expanded disability status scale; SD= standard deviation.